دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart Failure
Safia Chatur, MD, a Brian L. Claggett, P HD, a Finnian R. McCausland, MD, b Jean Rouleau, MD,c Michael R. Zile, MD,d Milton Packer, MD,e Marc A. Pfeffer, MD, P HD, a Martin Lefkowitz, MD, f John J.V. McMurray, MD,g Scott D. Solomon, MD, a Muthiah Vaduganathan, MD, MPH
doi : 10.1016/j.jacc.2023.02.009
Volume 81, Issue 15, 18 April 2023, Pages 1443-1455
Some patients with heart failure may experience transient changes in kidney function upon transition to sacubitril/valsartan. Whether such changes portend adverse outcomes or influence long-term treatment benefits with sacubitril/valsartan continuation is unknown.
Learning to Embrace the Decline in eGFR After Initiation of Therapies for Heart Failure∗
Steven G. Coca, DO, MS
doi : 10.1016/j.jacc.2023.02.024
Volume 81, Issue 15, 18 April 2023, Pages 1456-1458
Heart Failure Following Anti-Inflammatory Medications in Patients With Type 2 Diabetes Mellitus
Anders Holt, MD,a,b, * Jarl E. Strange, MD, a,c Nina Nouhravesh, MD,a Sebastian Kinnberg Nielsen, MB SC,a Mariam Elmegaard Malik, MD, a Anne-Marie Schjerning, MD, P HD, d,e Lars Køber, MD, DMSC,c,f Christian Torp-Pedersen, MD, DMSC,g,h Gunnar H. Gislason, MD, PHD,a,e,h,i Patricia McGettigan, MD, BSC (PHARM),j Morten Schou, MD, PHD,a,f Morten Lamberts, MD, PHD
doi : 10.1016/j.jacc.2023.02.027
Volume 81, Issue 15, 18 April 2023, Pages 1459-1470
Fluid retention and endothelial dysfunction have been related to use of nonsteroidal anti-inflammatory drugs (NSAIDs), and type 2 diabetes mellitus (T2DM) has been linked to both a decline in kidney function and subclinical cardiomyopathy.
Nonsteroidal Anti-Inflammatory Drugs and Type 2 Diabetes: A Recipe for Heart Failure?∗
Hassan Khan, MD, P HD, a Setor K. Kunutsor, MD, P HD
doi : 10.1016/j.jacc.2023.02.026
Volume 81, Issue 15, 18 April 2023, Pages 1471-1473
Impact of Age and Sex on Left Ventricular Remodeling in Patients With Aortic Regurgitation
Emmanuel Akintoye, MD, MPH,a Yoshihito Saijo, PHD, a Lorenzo Braghieri, MD, b Osamah Badwan, MD, b Hardik Patel, MD, b M Marwan Dabbagh, MD, b Joseph El Dahdah, MD,a Christine L. Jellis, MD, PH D, a Milind Y. Desai, MD, MBA, a L. Leonardo Rodriguez, MD, a Richard A. Grimm, MD, a Brian P. Griffin, MD, a Zoran B. Popovic, MD, PH D
doi : 10.1016/j.jacc.2023.02.037
Volume 81, Issue 15, 18 April 2023, Pages 1474-1487
Current guidelines for aortic regurgitation (AR) recommend the same linear left ventricular (LV) dimension for intervention regardless of age and sex.
Timing for Intervention in Aortic Regurgitation: When One Does Not Fit All∗
Anna Sannino, MD, P HD, a,b Federico Fortuni, MD
doi : 10.1016/j.jacc.2023.02.036
Volume 81, Issue 15, 18 April 2023, Pages 1488-1490
Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Risk Factors Under the Inflation Reduction Act
Prihatha R. Narasimmaraj, MD, a,b Andrew Oseran, MD, MBA, a,c Archana Tale, MPH,a Jiaman Xu, MPH,a Utibe R. Essien, MD, MPH,d,e Dhruv S. Kazi, MD, MS, a Robert W. Yeh, MD, MS C,a Rishi K. Wadhera, MD, MPP, MP HIL
doi : 10.1016/j.jacc.2023.02.002
Volume 81, Issue 15, 18 April 2023, Pages 1491-1501
High out-of-pocket prescription drug costs contribute to financial toxicity, medication nonadherence, and adverse cardiovascular (CV) outcomes. Policymakers recently passed the Inflation Reduction Act, which will cap Medicare out-of-pocket drug costs at $2,000/year and expand full low-income subsidies (LIS). It is unclear how these provisions will affect Medicare beneficiaries with CV risk factors and/or conditions.
Prescription for Affordable Health Care: Promise and Perils of Inflation Reduction Act Tackling Financial Toxicity∗
Khurram Nasir, MD, MPH, MSC ,a,b Joseph A. Salami, MD, MPH,c Elias Mossialos, MD, PHD
doi : 10.1016/j.jacc.2023.02.028
Volume 81, Issue 15, 18 April 2023, Pages 1502-1504
Evolving Science on Cardiovascular Disease Among Hispanic/Latino Adults: JACC International
Amber Pirzada, MD,a, * Jianwen Cai, PH D, b, * Gerardo Heiss, MD, PHD, c,y Daniela Sotres-Alvarez, D RPH, b Linda C. Gallo, P HD, d Marston E. Youngblood, MA, MPH,b M. Larissa Avilés-Santa, MD, MPH,e Hector M. González, PHD, f Carmen R. Isasi, MD, PH D, g Robert Kaplan, PHD, g,h John Kunz, MS,i James P. Lash, MD,j David J. Lee, PHD, k Maria M. Llabre, PHD, l Frank J. Penedo, PH D, l Carlos J. Rodriguez, MD, MPH,m Neil Schneiderman, PHD, l Tamar Sofer, PH D, n,o Gregory A. Talavera, MD, MPH,d Bharat Thyagarajan, MD, P HD, p Sylvia Wassertheil-Smoller, PHD, g Martha L. Daviglus, MD, P HD a
doi : 10.1016/j.jacc.2023.02.023
Volume 81, Issue 15, 18 April 2023, Pages 1505-1520
The landmark, multicenter HCHS/SOL (Hispanic Community Health Study/Study of Latinos) is the largest, most comprehensive, longitudinal community-based cohort study to date of diverse Hispanic/Latino persons in the United States.
Cardiovascular Health in Hispanic/Latino Patients: From Research to Practice∗
Fatima Rodriguez, MD, MPH,a Vanessa Blumer, MD
doi : 10.1016/j.jacc.2023.02.025
Volume 81, Issue 15, 18 April 2023, Pages 1521-1523
Supervised Exercise Training for Chronic Heart Failure With Preserved Ejection Fraction: A Scientific Statement From the American Heart Association and American College of Cardiology
doi : 10.1016/j.jacc.2023.02.012
Volume 81, Issue 15, 18 April 2023, Pages 1524-1542
JACC Journals’ Pathway Forward With AI Tools: The Future Is Now
Valentin Fuster, MD, PH D, Editor-in-Chief, Journal of the American College of Cardiology Biykem Bozkurt, MD, P HD, Editor-in-Chief, JACC: Heart Failure Y. Chandrashekhar, MD, DM, Editor-in-Chief, JACC: Cardiovascular Imaging Julia Grapsa, MD, PHD, Editor-in-Chief, JACC: Case Reports Bonnie Ky, MD, Editor-in-Chief, JACC: CardioOncology Douglas L. Mann, MD, Editor-in-Chief, JACC: Basic to Translational Science David J. Moliterno, MD, Editor-in-Chief, JACC: Cardiovascular Interventions Kalyanam Shivkumar, MD, PH D, Editor-in-Chief, JACC: Clinical Electrophysiology Candice K. Silversides, MD, Editor-in-Chief, JACC: Advances Justine Varieur Turco, MA, Divisional Vice President, American College of Cardiology Jian’an Wang, MD, PHD, Editor-in-Chief, JACC: Asia
doi : 10.1016/j.jacc.2023.02.030
Volume 81, Issue 15, 18 April 2023, Pages 1543-1545
Time to Benefit With Sotagliflozin in Patients With Worsening Heart Failure
Subodh Verma, MD, PhD *Deepak L. Bhatt, MD, MPH Nitish K. Dhingra, BHSc Ph. Gabriel Steg, MD Michael Szarek, PhD Michael Davies, PhD Marco Metra, MD Lars H. Lund, MD Bertram Pitt, MD
doi : 10.1016/j.jacc.2023.02.022
Volume 81, Issue 15, 18 April 2023, Pages 1546-1549
Mitral Valve Transcatheter Edge-to-Edge Repair in Patients With Cardiogenic Shock and Severe Mitral Regurgitation
Ahmed Elkaryoni, MD Gregg W. Stone, MD
doi : 10.1016/j.jacc.2022.12.031
Volume 81, Issue 15, 18 April 2023, Page e129
Reply: Mitral Valve Transcatheter Edge-to-Edge Repair in Patients With Cardiogenic Shock and Severe Mitral Regurgitation
Trevor Simard, MD Sreek Vemulapalli, MD Benjamin Hibbert, MD, PhD *Mohamad Alkhouli, MD
doi : 10.1016/j.jacc.2023.01.046
Volume 81, Issue 15, 18 April 2023, Page e131
